Plain-English translation of NCT07199764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications— and —designed to boost your immune system to fight pancreatic cancer. You would receive this treatment as a 'maintenance' therapy, meaning after your initial chemotherapy has done its job of shrinking or stabilizing your cancer. The trial will compare how well patients do on this new treatment versus similar patients who receive standard care.
Pancreatic cancer is very difficult to treat, and even when chemotherapy works at first, the cancer often comes back or keeps growing. This medication is being tested to see if it can help keep the cancer under control longer by training your body's immune system to continue fighting the cancer cells.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, you would receive the new medication through a regular schedule of visits to the study center. You would also need to have blood tests and imaging scans to see how your cancer is responding, and tumor biopsies (small tissue samples) to help researchers understand how the treatment is working. The study includes a safety check in the first month, after which the team will know whether to continue as planned or adjust the dose. You would be compared with an observational group of similar patients who either chose not to participate or whose medical records are reviewed to provide additional information about how patients like you typically do.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Pennsylvania
Collaborators
Lustgarten Foundation
Enrollment target
~100 participants
Started
November 2025
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Abramson Cancer Center Clinical Trials Service
University of Pennsylvania
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.